Table 2.
Sildenafil | Placebo | P valuea | |||||||
---|---|---|---|---|---|---|---|---|---|
Baseline | 30 min | 45 min | 60 min | Baseline | 30 min | 45 min | 60 min | ||
MAP, mm Hg | 93±3 | 92±3 | 91±3 | 89±3 | 93±3 | 95±4 | 96±3 | 96±4 | 0.001 |
HR, bpm | 53±3 | 57±4 | 55±4 | 55±4 | 55±3 | 53±3 | 55±4 | 52±3 | 0.03 |
FVR, mm Hg • min • 100mL/mL | 36±4 | 35±5 | 37±6 | — | 31±3 | 39±6 | 38±5 | — | 0.16 |
FBF, ml/min/100ml tissue | 2.8±0.3 | 2.9±0.3 | 2.7±0.3 | — | 3.2±0.3 | 2.8±0.3 | 2.8±0.3 | — | 0.19 |
Abbreviations: bpm, beats per minute; FBF, forearm blood flow; FVR, forearm vascular resistance; HR, heart rate; MAP, mean arterial pressure.
aAnalysis of variance: group × time interaction (group = sildenafil or placebo).